Indian court slams influencer after 71 suffer reactions to homemade hair oil
The incident in question took place on 16 March at an unauthorised hair treatment camp in Sangrur city, located in the northwestern state of Punjab. Amandeep Singh, who had over 85,000 followers on social media and owns a salon in Sangrur, is accused of claiming his homemade oil could treat baldness, and applying it on attendees.
The attendees were told to wash off the oil after 10-15 minutes as part of the treatment, after which they began to feel a burning sensation in their eyes, as well as redness and swelling on their faces, according to The Times of India.
The oil was being sold for Rs 1,300 (£11.42).
Local media spoke to several doctors in the area, who confirmed treating patients who had attended the camp the next day with these symptoms and diagnosed them as having contact dermatitis. A week later, it was confirmed that a total of 71 people, of the 500 who attended, had adverse effects from the oil.
Doctors also reportedly said that if the oil had affected the cornea, victims could have lost their vision.
The police confirmed that no permission had been granted for the camp.
In court on 12 May, Mr Singh's counsel argued that the influencer had applied for a patent for his oil and the reactions were because the victims did not apply it correctly. He added that Mr Singh worked as a hairstylist and was trying to help people suffering from hair loss.
Denying him anticipatory bail, the Punjab and Haryana high court came down heavily on influencers peddling unverified and untested products, saying: 'This is yet another unfortunate example of internet-famous, unqualified quacks taking advantage of the common man's insecurities.'
'In a bid to meet fickle societal standards of beauty, vulnerable people go to extreme lengths and even undergo risky procedures. The constant pressure to look a certain way often has a deleterious effect on the mental health of children and adults alike,' the high court observed in its order, according to Live Law.
'In fact, in this day and age where social media and marketing agendas so deeply affect one's self-esteem, we, as a society, must endeavour to promote authenticity over curated perfection.
'Advertising tall, misleading claims without scientific backing must be condemned.'
Mr Singh is reportedly absconding, and one of his associates has been arrested, according to the Hindustan Times.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
10 hours ago
- Daily Mail
Skye Wheatley has another procedure done on her eyes - following controversial fox eye surgery: 'They're horrible'
Skye Wheatley revealed on Friday she recently had another surgery done on her eyes, following her controversial 'fox eye' cosmetic procedure last year. The influencer, 31, shared videos to Instagram explaining to her followers this time it was medically necessary to go under the knife. Appearing in the clips with shocking bloodshot eyes, Skye said she had her pinguecula removed—a raised growth on the mucous membrane of the eye. 'I thought I would give an update on my eyeballs. They're horrible. It's really making me feel not my best, which is annoying,' she told her fans. 'I feel like they're going to be red for quite some time. I had my stitches out. The annoying thing is I'm just not seeing an improvement.' From A-list scandals and red carpet mishaps to exclusive pictures and viral moments, subscribe to the DailyMail's new showbiz newsletter to stay in the loop. Skye leaned in to the camera to show followers how irritated and bloodshot her eyes looked following the medical surgery. 'Nothing will make you feel worse and uglier than bloodshot eyes. This is going to be the situation for at least another two to three weeks,' she said. She then assured followers: 'It's not a virus. I had pinguecula surgery. I had my pingueculae removed.' According to Johns Hopkins Medicine, a pinguecula is a small, yellowish growth which appears on the conjunctiva of the eye. It is a common and benign condition often caused by sun exposure and dry, dusty environments. Pingueculae are usually only surgically removed if they become painful, affect how the patient blinks, or impair their vision. It comes after Skye underwent a controversial fox eye lift surgery, among several other procedures, in Turkey last October. Skye also had liposuction, a complimentary temporal lift, and a blepharoplasty. A temporal lift is a fat transfer into the face to prevent the need for injectable dermal fillers, and a blepharoplasty is an eyelid surgery. 'My doctor said there wasn't much fat on my arms or legs so [he] only took the littlest bit and from what I can see of my arms so far I'm really happy,' Skye said. 'Legs don't look much different, probably swollen.' Answering a question on her Instagram Stories, Skye listed off all the plastic surgery procedures she's ever had done. She mentioned surgery on her nose, her breasts (twice), arms, inner thigh, and face. The influencer previously revealed she couldn't open her eyes for three days following the fox eye lift procedure. 'Being in a foreign hospital with no eyesight was pretty unsettling,' she said. 'Why did you get the liposuction if you're really fit?' another follower asked Skye. 'Because [it] doesn't matter how fit you are, you're always going to have stubborn areas of fat!' Skye wrote. 'I'm not actually that fit. Yes, I train daily, but my diet isn't perfect. I'm too much of a sweet tooth, I'm obsessed with sugar and food in general. I'm a big eater lol. 'He wasn't even going to do it, he said hardly any fat, but I insisted.' Skye was also forced to address accusations of a plastic surgery addiction shortly after she announced she was travelling to Turkey for the procedures. 'Really not being a hater—but YOU'RE the exact reason girls have self-esteem issues,' one follower wrote to her. 'Everyone is going to have self-esteem issues,' Skye replied. 'I know it's sad because I see the beauty in others but somehow it's always different when you look at yourself... 'And I'm being open and honest about my surgeries because I DON'T want other girls who aren't enhanced to feel like they're not "good enough" or "not pretty enough". 'Everyone is beautiful with or without surgery, but I think the more damaging thing is to get all these enhancements done without being honest about it. 'There are so many girls online who've had surgical enhancements and say nothing. I won't be one of those people.'
Daily Mail
3 days ago
- Daily Mail
Doctors remove tumor the 'size of a young child' from man's leg in groundbreaking operation
Doctors have removed a massive cancerous tumor the size of a young child from a man's leg. Mohd Salman, a 27-year-old from India, was diagnosed in 2019 with chondrosarcoma, a slow-growing cancer that forms in the connective tissue that protects the bones. For more than five years, the tumor in his leg grew slowly without causing him any pain. However, within the last six months, Salman's tumor ballooned in size to 76.5 pounds (34.7 kilograms), measuring four by two feet long - roughly the same weight as an eight-year-old child. Salman, a former laborer, was robbed of his ability to walk and completely bedridden in excruciating pain. After a handful of doctors across the Delhi and Uttar Pradesh areas of India failed to help Salman, orthopedic surgeon Dr Mohit Dhingra of AIMS Rishikesh hospital led the charge to remove the massive growth. On June 9, 2025, Dr Dhingra and his team removed the tumor entirely in a brutal six-hour operation. Dr Dhingra said: 'This was one of the most challenging operations we've taken on. The sheer weight and complexity of the tumor pushed our team to the edge of medical precision.' Chondrosarcoma is made up of cells in the cartilage, firm tissue that protects the end of the bones. It's most often found in the pelvis, hip or shoulder, though it can form in the spine in rare cases. The disease makes up one in four bone cancer cases in the U.S., adding up to 1,300 every year. The condition kills about one in five patients within the first five years. It's unclear if Salman's cancer spread to other organs or tissues, which could make his disease more difficult to treat. While chemotherapy and radiation can help control the spread of aggressive forms of chondrosarcoma, the main treatment is surgery. Salman's doctors first had to perform an MRI and an angiography, which visualizes blood vessels and arteries, to make sure they didn't hit any major structures during the operation. One wrong move could have led to severe bleeding and damage to any nearby organs. After six hours, doctors were able to remove the entire tumor with no complications. Hospital leadership have called the operation a landmark moment. Professor Meenu Singh, AIIMS-Rishikesh executive director, praised the surgical team's success, noting that it has raised the bar for handling extreme cases of rare cancers. Though the tumor was massive, it is dwarfed in comparison to other growths in medical literature. The largest tumor ever recorded, according to the Guinness Book of World Records, was 328 pounds (148.6). The growth was an ovarian tumor removed from a 43-year-old woman in 1906. More recently, in 2022, doctors in Brazil removed a 100-pound tumor from a 45-year-old woman after it grew for five years. It is unclear what kind of tumor it was. Salman is still hospitalized more than three weeks after the surgery and may need rehabilitation to learn how to walk and perform daily tasks again. He said: 'The doctors didn't just remove a tumor - they gave me my life back.'
Reuters
3 days ago
- Reuters
India File: The new gold rush for weight-loss drugs
(This was originally published in the India File newsletter, which is issued every Tuesday. Sign up here to get the latest news from India and how it matters to the world.) India has joined the global rush for weight-loss drugs as Novo Nordisk launched its popular Wegovy last week in the world's most populous country, just months after the arrival of rival Eli Lilly's Mounjaro. India's pharmaceutical powerhouses are also gearing up to launch generic versions of these drugs, putting it squarely on the map of what could become a $150 billion global market within the next 10 years. That's our focus this week. And, after a bountiful monsoon brought a bumper rice harvest, India is diverting record volumes to ethanol production to rein in inventories. Scroll down for more on that. From healthcare to esports, Asia's industries are evolving fast. Register, opens new tab to watch the live broadcast of the #ReutersNEXTAsia, opens new tab summit on July 9 to see how innovation is reshaping the region. ** China's rare earths are flowing again, but not freely ** Trump complains about US-Japan trade talks as Bessent warns of higher tariffs ** Thai Constitutional Court to weigh petition seeking PM's dismissal ** China's factory activity returns to growth in June, Caixin PMI shows India looks poised to become the next big battleground in the booming market for weight-loss drugs, its strong economic growth and rapidly rising rates of obesity drawing the attention of both global pharmaceutical giants and home-grown generics makers. Denmark's Novo Nordisk last week began selling its blockbuster drug Wegovy in India while competitor Eli Lilly introduced an easy-to-use version of its Mounjaro, in what Jefferies predicts could soon grow into a $1 billion market. That's still a small fraction of the worldwide market, worth $24 billion last year according to IQVIA, while various forecasts indicate it could reach $150 billion early in the next decade. Many forecasts, moreover, have been raised sharply over the past year, and both analysts and industry executives have marked India and other big emerging markets as an essential driver of that growth. India lags only China in the number of adults with diabetes and its obesity rates are on the rise. A government survey last year noted that rising incomes and urbanisation have boosted consumption of processed food and beverages. "Driven by unhealthy diets, sedentary lifestyles, and environmental factors, obesity is rising rapidly, impacting both urban and rural populations," Nadim Anwer, pharmaceuticals analyst at data and analytics firm GlobalData, wrote in a report last month. "This trend is driving market growth," Anwer said. A government health survey conducted from 2019 to 2021 found nearly one in four Indian adults was overweight or obese. Just five years earlier that figure was one in five. Looking at obesity alone, the World Obesity Federation estimated the rate among Indian adults at 8% in 2023, well below 22% in the U.S. But India's population is four times larger, and its adult obesity rate is forecast to keep rising to 11% by 2035. This has drawn the attention not just of overseas majors like Novo and Lilly. Indian pharmaceutical heavyweights such as Sun Pharma, Cipla, Dr. Reddy's, Lupin and Biocon are preparing to launch cheaper generic drugs once semaglutide, the active compound in Wegovy, goes off-patent in 2026. Analysts at Jefferies said these big drugmakers would be particularly well-placed to benefit, given the complexity of manufacturing the drugs. Read here for details on firms looking to enter this segment. But these weight-loss drugs aren't going cheap - at least for now. Wegovy and Mounjaro are priced between 17,000 rupees and 26,000 rupees a month, putting them out of reach for most Indians without insurance or deep pockets. That hasn't dimmed enthusiasm among India's burgeoning urban middle class. Doctors across the country reported a surge in patient enquiries, mirroring the global frenzy, and Lilly said the response has been positive in India. While the entry of generics is likely to drive costs down eventually, other question marks hang over these drugs. New research has shown that they have a smaller impact in real life than in trials, the Reuters Health Rounds newsletter noted in its June edition. You can sign up for that newsletter here. Moreover, the World Health Organization said late last year that, while the drugs carry "the possibility of an end to the obesity pandemic", they also risk leaving behind those without access to proper healthcare and could overshadow other efforts to improve health. The WHO is due to release a report soon that would nevertheless back the use of such drugs for adults globally. Read here for that exclusive report. What do you think about the future of weight-loss drugs in India? Could it become a top world market - and manufacturer - for the pharmaceutical industry's latest blockbuster? Write to me at opens new tab. India is diverting record volumes of rice to ethanol production as it struggles with unprecedented inventories of the grain, which are likely to swell further with the arrival of the new harvest. India in March lifted the last of its rice export restrictions, which were adopted two years ago in response to poor rains. Now, the world's No.3 oil importer and consumer of petroleum products wants to harness that bumper harvest to meet its growing energy needs. The government has set a target to increase the proportion of gasoline blended with ethanol to 20% by 2025-26. It nearly hit that target in May, reaching 19.8%, with help from surplus rice. Read this in-depth report by Reuters correspondent Rajendra Jadhav. The Dalai Lama will address a major Buddhist gathering this week ahead of his 90th birthday, as followers await clues about his succession that may end up provoking China. Beijing views the exiled Tibetan leader as a separatist and says it will appoint his successor, which the Dalai Lama rejects. He has previously said it is possible his reincarnation will be found outside China, perhaps in India. Discussions around reincarnation usually don't happen during a monk's lifetime but Tibet's chief state oracle, who is also in exile in India, has said Beijing's interference changed that. No longer just a matter of religious significance for the Dalai Lama's followers, the succession has taken on geopolitical significance for China, India and the United States. Reuters journalist Krishna N. Das explains the Dalai Lama's succession plans here.
